Page 351«..1020..350351352353..360370..»

Summit Therapeutics Announces Commencement of $100 Million Rights Offering

Posted: July 19, 2022 at 2:14 am

Menlo Park, CA, July 18, 2022 (GLOBE NEWSWIRE) --  Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it has commenced its previously-announced rights offering of up to $100 million of the Company’s common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 pm Eastern Time on August 8, 2022, the expiration date (the “Expiration Date”).

Read more:
Summit Therapeutics Announces Commencement of $100 Million Rights Offering

Posted in Global News Feed | Comments Off on Summit Therapeutics Announces Commencement of $100 Million Rights Offering

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Posted: July 19, 2022 at 2:14 am

BASEL, Switzerland, July 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 9 new employees with a grant date of July 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.

More here:
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Posted in Global News Feed | Comments Off on Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Aeterna Zentaris Announces Effective Date of Share Consolidation

Posted: July 19, 2022 at 2:14 am

TORONTO, ON, July 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has filed articles of amendment, to effect the previously announced share consolidation (or reverse stock split) (the “Consolidation”) of its issued and outstanding common shares (the “Common Shares”) on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares.

View original post here:
Aeterna Zentaris Announces Effective Date of Share Consolidation

Posted in Global News Feed | Comments Off on Aeterna Zentaris Announces Effective Date of Share Consolidation

AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and…

Posted: July 19, 2022 at 2:14 am

PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company’s Members approved Written Resolutions of a Majority of the Members (the “Resolutions”) on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member’s resolutions to be approved by written resolutions signed by a majority of the votes of all Members entitled to vote on the resolution at a general meeting.

Go here to see the original:
AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and...

Posted in Global News Feed | Comments Off on AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and…

Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the…

Posted: July 19, 2022 at 2:14 am

SAN CARLOS, Calif. and NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- On March 18, 2022 Brookline Capital Acquisition Corp. (“BCAC”), a life-science focused Special Purpose Acquisition Company (“SPAC”) affiliated with Brookline Capital Markets, a division of Arcadia Securities, LLC (“Brookline”), announced a proposed business combination with Apexigen, Inc. (“Apexigen”), a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology.

Read more here:
Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the...

Posted in Global News Feed | Comments Off on Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the…

Roche’s Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease

Posted: July 19, 2022 at 2:14 am

Basel, 19 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Elecsys® Amyloid Plasma Panel, an innovative new solution to enable Alzheimer’s disease to be detected earlier. The Elecsys Amyloid Plasma Panel test detects and measures Alzheimer’s disease biomarkers in blood plasma to indicate the need for further confirmatory testing for Alzheimer’s disease. Roche is the first in-vitro diagnostics manufacturer to receive this designation for a blood-based biomarker test for Alzheimer’s.Alzheimer's disease is the most common form of dementia. Dementia affects more than 55 million people worldwide with more than 10 million new cases each year.1 Barriers to early and accurate diagnosis of Alzheimer’s disease exist across the globe – up to 3 out of 4 people living with symptoms of Alzheimer’s disease have not been diagnosed2, and those who have received a diagnosis, on average waited 2.8 years."The key to transforming the life of people with Alzheimer’s disease is to diagnose as early as possible and intervene with the right care plans,” said Thomas Schinecker, CEO of Roche Diagnostics. "Our new diagnostics test has the potential to streamline a patient's journey, improving speed and access toward a confirmatory diagnosis, giving people with Alzheimer’s disease and their caregivers more time to plan and prepare for the future.”Currently, the diagnosis of Alzheimer’s disease is largely based on clinical symptoms, including cognitive assessment, with a significant number of patients diagnosed when their disease has already advanced. The Elecsys Amyloid Plasma Panel will be the first qualitative test that combines the result of the phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human plasma. Elevations in pTau occur in early stages of Alzheimer’s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer’s disease. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.The Elecsys Amyloid Plasma Panel has thus the potential to ensure better identification of patients that require further confirmatory testing. This could be done via PET scan or cerebrospinal fluid (CSF) testing, supporting a more timely and accessible diagnosis. In conjunction with other diagnostic tools and the work Roche is doing in developing potential new treatments, this could be an important building-block toward improved care and outcomes for people with Alzheimer’s disease.Roche has also received a Breakthrough Device Designation for the Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF in vitro diagnostic immunoassays measuring ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of dementia. About the Elecsys® Amyloid Plasma PanelThe Elecsys Amyloid Plasma Panel measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma. Elevations in pTau occur in early stages of Alzheimer’s, while the presence of APOE E4 constitutes the most common genetic risk factor for Alzheimer’s disease. The result is intended for consideration in conjunction with other clinical information to advise for further confirmatory testing with amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. Patients testing negative with the Elecsys Amyloid Plasma Panel are unlikely to be amyloid positive and should be investigated for other causes of cognitive decline.About Alzheimer's diseaseAlzheimer’s is a progressive, fatal disease of the brain that gradually destroys memory, thinking skills and problem solving and impairs daily functioning such as the ability to manage one's own activities. Biological changes are believed to start decades before clinical symptoms of Alzheimer’s become evident. Early signs and symptoms include memory loss, changes in mood or personality, decreased judgement, confusion, and challenges with problem-solving, finding the right word or familiar tasks.Alzheimer's disease is the most common form of dementia. Dementia affects more than 55 million people worldwide with more than 10 million new cases each year. Up to 3 in 4 people with dementia worldwide have not been diagnosed.Roche has an extensive Alzheimer’s portfolio, including technology designed to more effectively detect and diagnose Alzheimer’s disease and monitor disease progression and multiple treatment approaches and molecules that may address key pathways of Alzheimer’s disease. Data from two Phase III studies with Roche’s investigational treatment, gantenerumab, in early Alzheimer’s disease are anticipated in November 2022. About the Breakthrough Device DesignationThe Breakthrough Devices Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. This program is designed to expedite the development and review of these medical devices.About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.All trademarks used or mentioned in this release are protected by law.References[1] “Dementia.” World Health Organization, World Health Organization, 2 Sept. 2021, https://www.who.int/news-room/fact-sheets/detail/dementia#:~:text=Rates%20of%20dementia,and%20139%20million%20in%202050. [2] Alzheimer's Disease International. “Adi - over 41 Million Cases of Dementia Go Undiagnosed across the Globe – World Alzheimer Report Reveals.” Alzheimer's Disease International (ADI), 21 Sept. 2021, https://www.alzint.org/news-events/news/over-41-million-cases-of-dementia-go-undiagnosed-across-the-globe-world-alzheimer-report-reveals/. Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com

Read the original:
Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease

Posted in Global News Feed | Comments Off on Roche’s Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer’s disease

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Posted: July 19, 2022 at 2:14 am

Ad hoc announcement pursuant to Art. 53 LR

The rest is here:
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Posted in Global News Feed | Comments Off on Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium

Posted: July 19, 2022 at 2:14 am

eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium

Continue reading here:
eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium

Posted in Global News Feed | Comments Off on eureKARE launches synthetic biology studio network with inaugural biomedical studio in Belgium

What gene changes and blood could tell us about the opioid crisis – UCI News

Posted: July 19, 2022 at 2:14 am

Irvine, Calif., July 14, 2022 The role of gene alterations resulting from childhood adversity in adults addicted to heroin and a search for blood tests to predict addiction vulnerability are part of sweeping research that scientists are launching at the University of California, Irvine.

The nearly $3.5 million five-year project to understand the opioid crisis is a collaboration of the School of Biological Sciences and the School of Medicine, as well as the Irvine Center for Addiction Neuroscience. The National Institute on Drug Abuse is funding the work through an initiative to encourage research innovation.

Researchers will examine how early-life adversity influences epigenetics, or experience-induced changes in gene expression, and how they affect the likelihood of adult addiction.

We want to see how these epigenetic alterations interact with the heroin experience and if there are sex differences in these processes, said lead principal investigator Stephen Mahler, associate professor of neurobiology & behavior and a fellow in the Center for the Neurobiology of Learning and Memory.

For example, what happens upon using opioid drugs might be different between people who had scarcity of resources or chaotic environments as children and those who didnt, Mahler said. This could account for why some people become addicted to these drugs, while others dont.

He noted that earlier research shows opioid-addicted women were more likely than men to have experienced stressful circumstances as children, such as those resulting from growing up amid early-life adversity.

Examining the bloods capacity for revealing the propensity for addiction and other mental disorders is also part of the study. This work centers on extracellular vesicles, which are cell-produced droplets containing proteins and microRNAs. Researchers will compare these vesicles in blood samples and cerebral spinal fluid of rodents to learn if those in the blood hold clues about an individuals risk of addiction or other mental disorders. If so, it could mean blood screening can provide information about the brain that helps prevent and treat addiction and related conditions.

Gaining a better understanding of an individuals epigenetics and brain activity opens up powerful new possibilities, said Mahler. As an example, if someone suffers a broken leg and it is determined they are susceptible to addiction, they can be given an alternative treatment for pain. For people already dependent on opioids, we may be able to develop precise treatments that target the genetic activity causing the addiction.

Numerous other inquiries will also take place as part of the research project. Serving as principal investigators are Christie Fowler, associate professor of neurobiology & behavior and fellow, CNLM; Vivek Swarup, assistant professor of neurobiology & behavior; and Dr. Tallie Z. Baram, distinguished professor of pediatrics, anatomy & neurobiology and neurology, Danette Shepard Professor of Neurological Sciences, and fellow, CNLM. Marcelo Wood, professor of neurobiology & behavior and fellow, CNLM, is co-investigator.

Nearly 50,000 people nationwide died from opioid-related overdoses in 2019, according to the National Institute on Drug Abuse. It calls opioid misuse and addiction a serious national crisis that affects public health as well as social and economic welfare.

If you can tie the event through a quote or anecdote to our values or to research, academic, character or leadership excellence or entrepreneurial spirit, research, education or community service, so much the better.

About UCIs Brilliant Future campaign:Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success, health and wellness, research and more. TheSchool of Biological Sciences and School of Medicine play a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/school-of-biological-sciences/ andhttps://brilliantfuture.uci.edu/uci-school-of-medicine/.

About the University of California, Irvine:Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities and is ranked among the nations top 10 public universities byU.S. News & World Report. The campus has produced five Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 224 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide.For more on UCI, visitwww.uci.edu.

Media access: Radio programs/stations may, for a fee, use an on-campus ISDN line to interview UCI faculty and experts, subject to availability and university approval. For more UCI news, visit news.uci.edu. Additional resources for journalists may be found at communications.uci.edu/for-journalists.

Read the original post:
What gene changes and blood could tell us about the opioid crisis - UCI News

Posted in Epigenetics | Comments Off on What gene changes and blood could tell us about the opioid crisis – UCI News

Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More – EconoTimes

Posted: July 19, 2022 at 2:14 am

Written by: James Carnell

Dr. Nirmalya Saha

If all the DNA molecules that make up a single person were lightbulbs, epigenetic modulators would be the light switch. While it is factual that our DNA plays a large role in our personal makeup, overall health, and body functionality, the picture is much more complex. Even while in utero, developing fetuses can experience epigenetic changes that play a major role in what that future persons makeup will be. While many of these changes are a normal part of development and will continue to happen over time, epigenetic modulators can also trigger internal changes that are linked to serious diseases, such as cancer.

As a molecular biologist, Dr. Nirmalya Saha has dedicated his career to understanding the role epigenetic changes play in Leukemia and how these complex factors present themselves throughout the course of specific cancers. While his work is largely focused on the oncology space, Dr. Saha recognizes just how powerful epigenetics can be. If these light switches can cause disease in an otherwise healthy person, they might just be the secret to fighting a disease once it has become a reality.

Dr. Sahas Impact on the Epigenetics Space

Though the importance of epigenetics is becoming more widely known, often emphasized by new studies and medical research advancements, many professionals in the molecular biology field have begun to examine its role in certain body functions. For Dr. Saha, the focus has been on developing an understanding of how important the epigenetic regulator PRMT5 is in Acute Myeloid Leukemia as well as unpacking the dynamic between SETDB1 and suppressing Leukemia. These studies are about more than understanding a complex relationship; they are about finding a solution for diseases that take lives.

Acute Leukemia with MLL rearrangement makes up about 5-10% of cases in adults and a shocking 70% of cases in infants. This disease straps those affected with a devastating prognosis and low chances of survival. With Dr. Sahas research, its becoming more likely that science can create a novel inhibitor molecule to treat the disease and offer patients a better outlook. Even if his work stopped here, with this subset of patients, it would be extraordinary, but it goes much further.

The Future of Epigenetics

Epigenetic therapies can fight against many forms of cancer, completely revolutionizing the toolkit doctors and patients have access to when battling different types of the disease. If these therapies are effective for one subset of diseases, there is so much potential to develop similar therapies for a plethora of disease categories. The work Dr. Saha and other molecular biologists are doing right now will be the difference between a future patient living and dying, growing old to see their families flourish or being taken too soon.

Aside from treating diseases, epigenetics plays a large role in understanding how each body works on an individual level, almost providing a fingerprint of each person. Armed with this knowledge, epigenetic researchers are making leaps and bounds in the space of personalized medicine. If we can determine how a persons body will react to different factors, its possible to mitigate potential dangers and get ahead of medical problems before they even start.

The Future of Dr. Saha

Though he has already provided astounding research, advancing the molecular biology field and propelling medical capabilities, Dr. Saha does not seem to be slowing down. As his research uncovers more powerful information, he is reminded of why he started this career to begin with: to help people.

Today, Dr. Saha is a committed teacher and mentor, working in the Department of Pathology at the University of Michigan, Ann Arbor. His work has been featured in renowned publications such as BBA-Reviews on Cancer, Stem Cell Reports, and BMC Genomics. As an active member of the American Association of Cancer Research and the Sigma Xi Honor Society, Dr. Saha will continue on his path to saving lives through research.

This article does not necessarily reflect the opinions of the editors or management of EconoTimes

View original post here:
Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More - EconoTimes

Posted in Epigenetics | Comments Off on Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More – EconoTimes

Page 351«..1020..350351352353..360370..»